インスリンイコデックとセマグルチドの配合剤である新しい週1回投与薬イコセマが、2型糖尿病（T2D）患者の血糖値を毎日投与するインスリングラルギンと比較してどの程度コントロールできるかを調査する研究調査（COMBINE 4）

基本情報

NCT ID

NCT06269107

ステータス

完了

試験のフェーズ

第3相

試験タイプ

介入

目標被験者数

485

治験依頼者名

Novo Nordisk A/S

概要

This study will compare the new medicine IcoSema, which is a combination of insulin icodec and semaglutide, taken once a week, to insulin glargine (mentioned as insulin glargine in this form) taken daily in people with type 2 diabetes. The study will look at how well IcoSema controls blood sugar levels as compared to insulin glargine in people with type 2 diabetes who do not have their blood sugar properly controlled with other oral diabetes medicines. Participant will either get IcoSema or insulin glargine. Which treatment participants get is decided by chance. IcoSema is a new medicine that doctors cannot prescribe. Doctors can already prescribe insulin glargine in many countries. The study will last for about 11 months (47 weeks).

対象疾患

介入

依頼者（Sponsor）

実施施設 (7)